Showing results (151-160 of 2,408) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|February 16, 2013
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in BelgiumPierre Chevalier, Mark Lamotte, Hilde Van Campenhout, et al.Journal of Medical Economics|February 9, 2013
Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapyMachaon Bonafede, Timothy Juday, Greg Lenhart, et al.Journal of Medical Economics|April 6, 2013
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in SwedenSten Fredrikson, Euan McLeod, Nathaniel Henry, et al.Journal of Medical Economics|April 10, 2013
Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial populationMargarita Udall, Anthony Louder, Brandon T Suehs, et al.Journal of Medical Economics|April 30, 2013
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysisJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.Journal of Medical Economics|April 30, 2013
Utilities for advanced basal cell carcinomaS L Shingler, J Garside, K Samanta, et al.Journal of Medical Economics|June 7, 2013
Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studiesKerstin Brismar, Marianna Benroubi, Claudia Nicolay, et al.Journal of Medical Economics|July 2, 2013
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitisMachaon Bonafede, George J Joseph, Nicole Princic, et al.Journal of Medical Economics|May 3, 2012
Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimensJ D BelseyJournal of Medical Economics|November 18, 2009
Managing acute acetaminophen poisoning with oral versus intravenous N-acetylcysteine: a provider-perspective cost analysisAlbert Marchetti, Richard RossiterPageof 241